University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey Department of Neurology, Stroke Center, Turkey.
University of Health Sciences, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey Department of Neurology, Stroke Center, Turkey.
J Clin Neurosci. 2024 Jun;124:47-53. doi: 10.1016/j.jocn.2024.04.012. Epub 2024 Apr 20.
The awareness of nonocclusive thrombus has increased with the increasing frequency of imaging methods used for acute ischemic stroke; however, the best treatment for nonocclusive thrombi is still unknown. In this study, we examined how anticoagulants affect supra-aortic artery nonocclusive thrombus and clinical outcomes.
This study included 52 patients with transient ischemic attack or stroke who were diagnosed with nonocclusive thrombi on computed tomography angiography at admission. Patients were treated with anticoagulant treatment and grouped according to treatment modality (either unfractionated heparin or low molecular weight heparin) and treatment duration. Primary safety outcome was major bleeding defined as immediate and clnically significant hemorrhage. Anticoagulant treatment was continued until the thrombus was resolved as determined by consecutive weekly computed tomography angiography controls. After thrombus resolution, treatment was directed according to the underlying etiology. Antiaggregation treatment was the preferred treatment after thrombus resolution for patients with no observed etiology.
The affected internal carotid arteries were most frequently located in the cervical segment (48 %). Complete resolution was achieved within 2 weeks in 50 patients (96 %). The involved vasculature included the following: the extracranial carotid artery segments (n = 26, 50 %), intracranial ICA segments (n = 10, 19 %), basilar artery segments (n = 8, 15 %) and MCA segments (n = 7, 13 %). The most common underlying pathologies were atherosclerosis (n = 17), atrial fibrillation (n = 17), undetermined embolic stroke (n = 8), dissection (n = 7), and malignancy (n = 2). No symptomatic intra- or extracranial bleeding complications due to anticoagulant use were observed in any patient during the study period. A good functional outcome (modified Rankin scale score 0-2) was achieved in 49 patients (94 %) at 3 months. There was no significant difference between treatment type and duration in terms of reinfarction (p = 0.97 and p = 0.78, respectively).
Anticoagulant treatment is safe and effective in symptomatic patients with intracranial or extracranial artery nonocclusive thrombus, regardless of the anticoagulant type, thrombus location and size.
随着用于急性缺血性脑卒中的影像学方法的应用日益增多,人们对非闭塞性血栓的认识也有所提高;然而,非闭塞性血栓的最佳治疗方法仍不清楚。在这项研究中,我们研究了抗凝剂如何影响主动脉以上非闭塞性血栓和临床结局。
本研究纳入了 52 名因短暂性脑缺血发作或脑卒中而在入院时通过计算机断层血管造影术诊断为非闭塞性血栓的患者。这些患者接受抗凝治疗,并根据治疗方式(普通肝素或低分子肝素)和治疗持续时间进行分组。主要安全性结局为大出血,定义为即刻和临床显著的出血。抗凝治疗持续到每周连续计算机断层血管造影术检查显示血栓溶解为止。血栓溶解后,根据潜在病因进行治疗。对于没有观察到病因的患者,血栓溶解后首选抗聚集治疗。
受影响的颈内动脉最常位于颈段(48%)。50 例(96%)患者在 2 周内完全溶解。受累血管包括以下部位:颅外颈动脉段(n=26,50%)、颅内颈内动脉段(n=10,19%)、基底动脉段(n=8,15%)和大脑中动脉段(n=7,13%)。最常见的潜在病理为动脉粥样硬化(n=17)、心房颤动(n=17)、不明原因的栓塞性脑卒中(n=8)、夹层(n=7)和恶性肿瘤(n=2)。在研究期间,没有观察到任何患者因抗凝使用而发生症状性颅内或颅外出血并发症。在 3 个月时,49 例患者(94%)取得了良好的功能结局(改良Rankin 量表评分为 0-2)。在再梗死方面,治疗类型和持续时间之间没有显著差异(p=0.97 和 p=0.78)。
抗凝治疗对于颅内或颅外动脉非闭塞性血栓形成的有症状患者是安全有效的,无论抗凝剂类型、血栓位置和大小如何。